Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 18/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516333 | 1.00 | SIRT1 (0.55) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL26938750 | 0.87 | SIRT3 (0.45) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL24377964 | 0.84 | SIRT1 (0.54) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL24377995 | 0.83 | SIRT1 (0.43) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL24377970 | 0.83 | SIRT1 (0.53) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL29516215 | 0.82 | POLB (0.47) | TDP1 | |
| SCHEMBL24378150 | 0.82 | POLB (0.47) | TDP1 | |
| SCHEMBL24377997 | 0.80 | MAPT (0.50) | — | |
| SCHEMBL24378138 | 0.77 | SIRT1 (0.50) | SIRT1SIRT3TDP1SIRT2 | |
| SCHEMBL24378125 | 0.77 | SIRT1 (0.65) | SIRT1SIRT3TDP1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-116323571-A | Covalent inhibitors of Creatine Kinase (CK) and their use for the treatment and prevention of cancer | 丹娜法伯癌症研究院 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | CSNK1A1L, CKMT1A; CKMT1B, KHK | SIRT1 1935/4885SIRT3 653/4885TDP1 2480/4885 |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | SIRT1 935/4885SIRT3 493/4885TDP1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.